The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

Amgen (AMGN) and AstraZeneca (AZN) announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE ...

AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its ...

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...

The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...

AstraZeneca PLC (LON:AZN) announced a healthy earnings result recently, and the market rewarded it with a strong uplift in ...

On BeiGene’s very first live earnings call, CEO and co-founder John Oyler on Thursday described a “once-in-a-lifetime ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

Results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in combination with a ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...